New Anticoagulants for Stroke Prevention in Atrial Fibrillation

Published Online: Tuesday, January 14, 2014
Follow Pharmacy_Times:
Christian Ruff, MD, MPH, of Harvard Medical School, gives an overview of the anticoagulants currently available for prevention of stroke in patients with atrial fibrillation.

Related Articles
The FDA’s Cardiovascular and Renal Drugs Advisory Committee has recommended the approval of edoxaban (Savaysa) for treating patients with nonvalvular atrial fibrillation, a type of arrhythmia that can potentially cause a stroke.
A new study indicates that high doses of fish oil supplementation fails to prevent the recurrence of atrial fibrillation.
When association is association and causation is causation.
Updated guidelines for postoperative atrial fibrillation contain several pieces of information for pharmacists to help prevent medication errors.
Latest Issues
$auto_registration$